Merck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patientsMarket Watch • 04/15/21
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19Business Wire • 04/15/21
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health WeekBusiness Wire • 04/14/21
Rose 95 Stock Portfolio March Madness Q1 Update Including Cost/Share And Purchase Evaluation ListSeeking Alpha • 04/13/21
Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney CancerBenzinga • 04/08/21
Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following SurgeryBusiness Wire • 04/08/21
IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma PatientsBenzinga • 04/07/21